cas 5190-68-1|| where to buy 4-chloroquinazoline

Nom du produit:4-chloroquinazoline

IUPAC Name:4-chloroquinazoline

Unité d'emballage	Stock disponible	Prix($)
CM114974-5g	in stock	ƄŢ
CM114974-10g	in stock	ŉǊƄ
CM114974-25g	in stock	ǊǵȎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 5190-68-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:5190-68-1; Formule moléculaire:C8H5ClN2; Point de fusion:-; Code SMILES:ClC1=C2C=CC=CC2=NC=N1; Densité:

: Numéro de catalogue:CM114974; Poids moléculaire:164.59; Point d'ébullition:281.0±13.0°C at 760 mmHg; N° Mdl:MFCD00228682; Stockage:Keep in inert atmosphere, store at 2-8°C.

: Quinazolines; Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

: Bexotegrast; Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.